Context: It’s been almost a year since the Munich I Regional Court granted Halozyme a preliminary injunction (PI) against Merck over its Keytruda SC subcutaneous immunotherapy product (December 6, 2025 ip fray article).
What’s new: Yesterday, the Oberlandesgericht München (Munich Higher Regional Court) entered its decision in appeal no. 6 U 3726/25 e, overturning the lower court’s decision. The written reasons have yet to be handed down.
Direct impact:
- On the PI track, this is the final result. There is no possibility for Halozyme to get this decision overturned.
- But Halozyme has announced the filing of a regular complaint, seeking a permanent injunction at the end of full-blown proceedings. Halozyme stresses that the appeals court’s PI denial does not preclude the lower court from granting a permanent injunction. Technically, that is correct. Practically, however, any preliminary assessment by the appeals court that calls into question the merits of Halozyme’s case ups the ante for the next round.
Wider ramifications:
- Halozyme’s official reaction mentions “a Dutch patent court [having] prohibited Merck’s European Marketing Approval holder from committing an infringement in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands, by manufacturing or causing to be manufactured, offering, putting on the market or using Keytruda SC in those countries, or by importing it or holding it in stock for that purpose”.
- Halozyme also points out that Halozyme’s most lucrative licensing program, named ENHANZE, is not impacted as the MDASE patents at issue here are not part of the ENHANZE program.
- The outcome is a major win for Merck. But the Munich Higher Regional Court is notoriously slow to decide cases even when there are objective reasons to rule swiftly.
Court and counsel
Munich Higher Regional Court, 6th Civil Senate: Presiding Judge Lars Meinhardt, Judge Dr. Heister, and Judge Baumann.
Halozyme is being represented by Quinn Emanuel.
Hogan Lovells Cadwalader (ip fray firm profile) won this case for Merck.
